Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature

Immune checkpoint inhibitors (ICIs), including nivolumab, have exhibited substantial benefits in the treatment of several types of cancers. However, treatment with ICIs is often accompanied by immune-related adverse events (irAEs), and a clear understanding of the precise indications and management...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Clin Oncol
Autores principales: Izumi, Hiroki, Kodani, Masahiro, Kurai, Jun, Takeda, Kenichi, Okazaki, Ryota, Yamane, Kohei, Teruya, Yasuhiko, Yamamoto, Akihiro, Sueda, Yuriko, Yanai, Masaaki, Tanaka, Natsumi, Sakamoto, Tomohiro, Yamaguchi, Kosuke, Makino, Haruhiko, Igishi, Tadashi, Yamasaki, Akira
Formato: Artigo
Lenguaje:Inglês
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6781813/
https://ncbi.nlm.nih.gov/pubmed/31616560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1923
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares